Featured Stock to Focus: Valeant Pharmaceuticals International, Inc. (VRX)

22
bose headphone lawsuit

Valeant Pharmaceuticals International, Inc. (VRX) belonging to the Healthcare sector has surged 1.69% and closed its last trading session at $14.43.

The company reported its EPS on 6/29/2010.

The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 3 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 3 and 3.2 respectively.

Valeant Pharmaceuticals International, Inc. on 6/29/2010 reported its EPS as $0.58 with the analysts projecting the EPS of the stock as $0.49. The company beat the analyst EPS Estimate with the difference of $0.09. This shows a surprise factor of 0.184%.

Analysts are also projecting an Average Revenue Estimate for Valeant Pharmaceuticals International, Inc. as $297080 in the Current Quarter. This estimate is provided by 5 analysts.

The High Revenue estimate is predicted as 333000, while the Low Revenue Estimate prediction stands at 270800. The company’s last year sales total was 220320.

In the past 5 years, the stock showed growth of 61.43% per annum. While for the next 5 years, the growth estimate is 15.24%.

Valeant Pharmaceuticals International, Inc. (VRX) has the market capitalization of $5.05 Billion. The company rocked its 52-Week High of $28.59 and touched its 52-Week Low of $8.31.

The stock has Return on Assets (ROA) of -2.6 percent. Return on Equity (ROE) stands at -30.2% and Return on Investment (ROI) of -1.6 percent.

The stock is currently showing YTD performance of -0.62 Percent. The company has Beta Value of -0.38 and ATR value of 0.59. The Weekly and Monthly Volatility stands at 2.90% and 3.64%.